GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mallinckrodt PLC (OTCPK:MNKKQ) » Definitions » Debt-to-EBITDA

Mallinckrodt (Mallinckrodt) Debt-to-EBITDA : -0.07 (As of Sep. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Mallinckrodt Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mallinckrodt's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $377 Mil. Mallinckrodt's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0 Mil. Mallinckrodt's annualized EBITDA for the quarter that ended in Sep. 2023 was $-5,776 Mil. Mallinckrodt's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.07.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Mallinckrodt's Debt-to-EBITDA or its related term are showing as below:

MNKKQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.22   Med: 5.44   Max: 20.25
Current: -0.29

During the past 12 years, the highest Debt-to-EBITDA Ratio of Mallinckrodt was 20.25. The lowest was -16.22. And the median was 5.44.

MNKKQ's Debt-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.665 vs MNKKQ: -0.29

Mallinckrodt Debt-to-EBITDA Historical Data

The historical data trend for Mallinckrodt's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mallinckrodt Debt-to-EBITDA Chart

Mallinckrodt Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.15 -16.22 19.34 20.25 N/A

Mallinckrodt Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -43.73 19.64 28.57 9.22 -0.07

Competitive Comparison of Mallinckrodt's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Mallinckrodt's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mallinckrodt's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mallinckrodt's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Mallinckrodt's Debt-to-EBITDA falls into.



Mallinckrodt Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Mallinckrodt's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(44.1 + 3027.7) / N/A
=N/A

Mallinckrodt's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(377.4 + 0) / -5776
=-0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


Mallinckrodt  (OTCPK:MNKKQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Mallinckrodt Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Mallinckrodt's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Mallinckrodt (Mallinckrodt) Business Description

Traded in Other Exchanges
N/A
Address
College Business and Technology Park, Cruiserath, Blanchardstown, Dublin, IRL, 15
Mallinckrodt PLC develops, manufactures, markets, and distributes specialty pharmaceutical products and therapies. Its areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. The company operates its business in two reportable segments namely Specialty Brands which include specialty pharmaceutical brands; and Specialty Generics which includes niche specialty generic drugs and active pharmaceutical ingredients. It generates maximum revenue from the Specialty Brands segment. Geographically, it derives a majority of its revenue from the United States.
Executives
Sigurdur O Olafsson director, officer: President and CEO 360 MOUNT KEMBLE AVENUE, MORRISTOWN NJ 07960
Myers Woodrow A Jr director 1 N ILLINOIS SREET 2101, INDIANAPOLIS IN 46204
Fyi S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Ffi Iii S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Olifant Luxco S.a R.l. 10 percent owner 19, RUE DE BITBOURG, LUXEMBOURG N4 L-1273
Daniel Arthur Celentano director 2831 S. BAYSHORE DRIVE, UNIT 2103, MIAMI FL 33133
Riad Hussein El-dada director 910 TALAMORE DRIVE, AMBLER PA 19002
Bracebridge Capital, Llc 10 percent owner 888 BOYLSTON STREET, SUITE 1500, BOSTON MA 02199
Kassie Harrold officer: Chief Compliance Officer C/O MALLINCKRODT PHARMACEUTICALS, 675 MCDONNELL BLVD., HAZELWOOD MO 63042
Neal P Goldman director 10700 PARKRIDGE BLVD., RESTON VA 20191
Steven J. Romano officer: EVP & Chief Sci. Ofcr 675 MCDONNELL BLVD., HAZELWOOD MO 63042
David Y Norton director 8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Carlos V Paya director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Anne Clem Whitaker director 109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James R Sulat director

Mallinckrodt (Mallinckrodt) Headlines

From GuruFocus